undamentalytics Newsletter
Sign in

Arbutus Biopharma Corp income statement

In fiscal 2025, Arbutus Biopharma Corp reported revenue of $14.1m, up 128.2% on the year before, operating income of −$38.2m (a -271.0% margin) and net income of −$33.5m, or −$0.17 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1714151523111667113918614182
Research and development20182139526163585849668474542518
General and administrative6869263916161815171822221616
Operating income−11−13−12−33−104−492−111−90−144−58−74−65−78−76−38149
Interest expense————000024320000
Income before tax——−14−39−79−489−109−61−166−64——————
Income tax——00−16−105−24−4−13004000—
Net income−1030−14−39−63−384−84−57−154−64−76−69−73−70−34153
Diluted EPS−$0.45$1.03−$0.46−$0.90−$1.38−$7.24−$1.56−$1.21−$2.89−$1.00−$0.83−$0.46−$0.44−$0.38−$0.17$0.79
Diluted shares (average)23m29m31m43m45m53m55m55m57m76m106m151m166m186m192m194m
EBITDA−10−12−12−33−103−491−109−88−142−56−72−64−77−75−38149

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ABUS vs URGNABUS vs NUVBABUS vs VALNABUS vs IBRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Arbutus Biopharma Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arbutus Biopharma Corp.